Compliance certificate on share dematerialization for Sep 2026 quarter

Compliance View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.0%Reaction day

₹29.80

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%+0.3% vs market

Pharmaceuticals peers, median of 172sector-0.0%+1.1% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250 and 1.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.0+0.7+0.3-0.0+1.1

Next day

+2.3-1.0+3.3-0.8+3.2

+0.7-0.3+1.0-0.6+1.3

+0.7-1.9+2.6-1.9+2.6

-2.0-4.5+2.5-3.5+1.5

-4.4-5.5+1.1-4.4+0.0

-4.0-7.3+3.3-4.4+0.4

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Pharmaids Pharmaceuticals filed a routine compliance certificate under SEBI Regulation 74(5) for the quarter and half year ended September 30, 2026. The certificate, issued by its Registrar Venture Capital and Corporate Investments, confirms that shares received for dematerialization were properly cancelled and depository records (NSDL and CDSL) were updated within 15 days, as required by the regulation.

Likely market impact

Routine procedural filing with no material business or price impact. Standard SEBI compliance requirement.